Numedicus’ approach to new products is based on therapeutic switches, namely new uses for known drugs, and alternatively called ‘drug reprofiling’, ‘drug repositioning’ or ‘drug repurposing’.Therapeutic switch projects are attractive because they can be commercialised more quickly, and with lower risk than medicines resulting from traditional